Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

NCT00002798 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00002798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
August 31, 1996
Completion date
Not reported
Enrollment
880 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood acute erythroleukemia (m6), childhood acute megakaryocytic leukemia (m7), childhood acute monoblastic leukemia (m5a), childhood acute monocytic leukemia (m5b), childhood acute myeloblastic leukemia with maturation (m2), childhood acute myeloblastic leukemia without maturation (m1), childhood acute myelomonocytic leukemia (m4), childhood myelodysplastic syndromes, chronic myelomonocytic leukemia, de novo myelodysplastic syndromes, refractory anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory anemia with ringed sideroblasts, secondary myelodysplastic syndromes, untreated childhood acute myeloid leukemia and other myeloid malignancies